Sophie Caillard
YOU?
Author Swipe
View article: Shiga Toxin–Producing Escherichia coli–Associated Hemolytic Uremic Syndrome in Adult Kidney Transplant Recipients
Shiga Toxin–Producing Escherichia coli–Associated Hemolytic Uremic Syndrome in Adult Kidney Transplant Recipients Open
This study highlights that STEC-HUS represents a serious complication in KTRs, significantly impairing renal and overall survival. It should be systematically considered in cases of de novo posttransplant TMA, whether in the absence of pro…
View article: From Risk Assessment to Management: Cardiovascular Complications in Pre- and Post-Kidney Transplant Recipients: A Narrative Review
From Risk Assessment to Management: Cardiovascular Complications in Pre- and Post-Kidney Transplant Recipients: A Narrative Review Open
Kidney transplantation remains the best treatment for chronic kidney failure, offering better outcomes and quality of life compared with dialysis. Cardiovascular disease (CVD) is a major cause of morbidity and mortality in kidney transplan…
View article: Diagnostic Value of Biological Parameters in Biopsy-Confirmed Thrombotic Microangiopathy–MATRIX Consortium Group
Diagnostic Value of Biological Parameters in Biopsy-Confirmed Thrombotic Microangiopathy–MATRIX Consortium Group Open
Common biological parameters miss the diagnosis in more than 50% of TMA except when fibrinogen is < 5 g/l, creatinine ≥ 300 μmol/l, and PT < 90%. Schistocyte reporting is heterogenous, and its results are usually deceptive in TMA.
View article: Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation Open
TMA after ABOi transplantation is not a rare phenomenon and is associated with a poor prognosis in nonresponders-to-treatment patients. ABGA titer performed by hemagglutination is an imperfect marker of the occurrence of such a phenomenon.
View article: Fumagillin Shortage: How to Treat Enterocytozoon bieneusi Microsporidiosis in Solid Organ Transplant Recipients in 2024?
Fumagillin Shortage: How to Treat Enterocytozoon bieneusi Microsporidiosis in Solid Organ Transplant Recipients in 2024? Open
Intestinal microsporidiosis caused by Enterocytozoon bieneusi is an opportunistic infection that especially affects solid organ transplant (SOT) recipients. Management revolves around tapering the immunosuppressive regimen and/or using a s…
View article: Extracellular Fluid Volume and Mortality after Kidney Transplantation
Extracellular Fluid Volume and Mortality after Kidney Transplantation Open
Key Points Post-transplantation extracellular fluid volume (ECV) is not only influenced by recipient characteristics and allograft function, but also by transplantation-specific factors. In multivariable cause-specific Cox analyses, increa…
View article: In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients
In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients Open
International audience
View article: Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft
Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft Open
Background Recurrence of focal segmental glomerulosclerosis (FSGS) is common after kidney transplantation and is classically associated with a significant decrease in graft survival. A major risk factor is a prior history of FSGS recurrenc…
View article: #1940 Plasma complement activation profile in kidney transplant recipients with IgAN supports the importance of the complement alternative pathway in IgAN
#1940 Plasma complement activation profile in kidney transplant recipients with IgAN supports the importance of the complement alternative pathway in IgAN Open
Background and Aims The alternative complement and lectin pathways are key players in IgA nephropathy (IgAN). However, the precise dynamics of complement activation in IgAN remain poorly understood. Non-invasive complement biomarkers are u…
View article: #2663 Assessment of in situ alternative and classical convertases as indicators of ongoing glomerular complement activation in IgA nephropathy
#2663 Assessment of in situ alternative and classical convertases as indicators of ongoing glomerular complement activation in IgA nephropathy Open
Background and Aims Complement activation is involved in IgA nephropathy (IgAN), opening up new avenues for complement-targeting therapies. However, precise patient selection and optimal timing for these therapies are essential. Current di…
View article: #2639 Unraveling complement activation profiles on endothelial cells in healthy donors using an ex vivo model
#2639 Unraveling complement activation profiles on endothelial cells in healthy donors using an ex vivo model Open
Background and Aims Complement is involved in numerous kidney diseases. However, functional approaches to properly examine individual's susceptibility to complement dysregulation are limited. Method We assessed ex vivo complement activatio…
View article: Living During COVID-19 While Immunocompromised: A Patient and Physician Perspective from France
Living During COVID-19 While Immunocompromised: A Patient and Physician Perspective from France Open
This article is co-authored by a kidney transplant recipient and her nephrologist. By sharing her personal experience of the coronavirus disease 2019 (COVID-19) pandemic, the patient illustrates the concerns of immunocompromised patients d…
View article: Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics
Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics Open
Aims Eculizumab is a monoclonal antibody targeting complement protein C5 used in renal diseases. As recommended dosing regimen leads to unnecessarily high concentrations in some patients, tailored dosing therapeutic drug monitoring was pro…
View article: Aortobifemoral Bypass in Kidney Transplant Candidates: A Ten-Year Experience
Aortobifemoral Bypass in Kidney Transplant Candidates: A Ten-Year Experience Open
In patients with severe aorto-iliac calcifications, vascular reconstructions can be performed in order to allow kidney transplantation. The aim of this study was to analyze the outcomes of kidney transplant candidates who underwent an aort…
View article: The complement system in IgAN: mechanistic context for therapeutic opportunities
The complement system in IgAN: mechanistic context for therapeutic opportunities Open
The complement system plays a crucial role in innate immunity, providing essential defense against pathogens. However, uncontrolled or prolonged activation of the complement cascade can significantly contribute to kidney damage, especially…
View article: Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines
Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines Open
Imlifidase recently received early access authorization for highly sensitized adult kidney transplant candidates with a positive crossmatch against an ABO-compatible deceased donor. These French consensus guidelines have been generated by …
View article: Urinary collagen peptides: Source of markers for bone metabolic processes in kidney transplant recipients
Urinary collagen peptides: Source of markers for bone metabolic processes in kidney transplant recipients Open
Introduction: Kidney transplant recipients (KTRs) are at an increased risk of fractures. Total urinary hydroxyproline excretion served as marker for bone resorption (BR) but was replaced by β‐CrossLaps (CTX), a C‐terminal collagen α‐1(I) c…
View article: Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients
Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients Open
The concomitant use of the monoclonal antibodies (mAbs) tixagevimab-cilgavimab has been originally authorized for pre-exposure prophylaxis of COVID-19.1 Although limited by a weak neutralizing activity,2 tixagevimab-cilgavimab has been the…
View article: #5876 ISLET TRANSPLANTATION VERSUS INSULIN ALONE IN TYPE 1 DIABETIC KIDNEY TRANSPLANT RECIPIENTS: A FRENCH NATIONWIDE STUDY ON BEHALF OF THE TREPID GROUP
#5876 ISLET TRANSPLANTATION VERSUS INSULIN ALONE IN TYPE 1 DIABETIC KIDNEY TRANSPLANT RECIPIENTS: A FRENCH NATIONWIDE STUDY ON BEHALF OF THE TREPID GROUP Open
Background and Aims Islet transplantation is associated with a benefit on glycaemic control compared to optimized insulin therapy in recent clinical trials. However, there is a lack of evidence concerning the long-term impact of islet tran…
View article: Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients Open
International audience